Science drives oncology new product development and the AACR special conferences are always a good place…
How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development
Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.
How early evolutionary changes in cancer can impact hot/cold regions and patient outcomes
